Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation

Ann Rheum Dis. 2009 Nov;68(11):1787-8. doi: 10.1136/ard.2009.109702.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Adult
  • Antibodies, Anti-Idiotypic / biosynthesis*
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / immunology*
  • Antirheumatic Agents / therapeutic use
  • Drug Tolerance
  • Female
  • Humans
  • Male
  • Middle Aged
  • Spondylitis, Ankylosing / drug therapy
  • Spondylitis, Ankylosing / immunology*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Adalimumab